IOP increase more likely in patients who receive large number of bevacizumab injections

BALTIMORE — Bevacizumab has a substantially increased risk of clinically relevant IOP increase in patients who have received more than 25 injections compared with ranibizumab or aflibercept, according to a “hot topic” designated study at the Association for Research in Vision and Ophthalmology annual meeting.“Looking at this in a real-world situation instead of the strict clinical research setting, what we found is a lower rate of clinically significant sustained IOP increase, so only 2% or 3% in patients overall, and it didn’t really vary between drugs except with patients who had over 25 injections,” Elizabeth A. Atchison, MD, surgical retina fellow at Rush University and Illinois Retina Associates, told Healio.com/OSN in an interview.